High Science
Delivered.
Developing Next Generation Therapies for Lysosomal Storage Disorders
High Science
Delivered.
Developing Next Generation Therapies for Lysosomal Storage Disorders
A New Path
Unlocking the potential of mannose 6-phosphate (M6P), our breakthrough platform technology drives the development of next generation enzyme replacement and gene therapies for lysosomal storage disorders (LSDs).
Our mission is to translate the M6PT innovation into more effective next generation therapies for individuals affected by LSDs – to relieve suffering, to restore health, to increase hope, and to improve lives.
A New Path
Unlocking the potential of mannose 6-phosphate (M6P), our breakthrough platform technology drives the development of next generation enzyme replacement and for lysosomal storage disorders (LSDs).
Our mission is to translate the M6PT innovation into more effective next generation therapies for individuals affected by LSDs – to relieve suffering, to restore health, to increase hope, and to improve lives.
Our Main Focus
Our innovative S1S3 co-expression platform technology enables us to develop next generation, best-in-class, targeted enzyme replacement therapy (ERT) or gene therapy products to treat lysosomal storage disorders (LSDs).
Individuals & families
We Are Dedicated to the Individuals We Serve.
Support Resources
